Analytical considerations for cfDNA biomarker analysis powered by NGS
Powerful liquid biopsy: from multianalytes to ultrasensitive cfDNA analysis
A series of three liquid biopsy webinars about how you can get a complete picture by stabilizing and isolating multiple analytes from the same blood draw – to generate insights otherwise undetectable in single analytes. You will learn how to get started with multianalyte studies and how to analyze cfDNA using NGS and dPCR techniques.
The analysis of cell-free DNA (cfDNA) biomarkers using next-generation sequencing (NGS) is becoming increasingly important in cancer research due to its potential applications in early cancer detection, therapy selection, and minimal residual disease (MRD) monitoring. However, there are several challenges that need to be addressed in order to ensure accurate and reliable analysis of cfDNA. In this context, the use of NGS-based assays can provide high sensitivity and specificity in detecting low-level mutations in cfDNA. The success of NGS-based cfDNA analysis depends on several analytical considerations including overcoming sequencing reaction errors, enrichment biases and false positives to detect variant alleles down to 0.1% frequency.
In this webinar, you will learn about
- The value of cfDNA in cancer research
- The challenges associated with cfDNA analysis, and
- Analytical considerations for NGS-based cfDNA biomarker analysis